Compare Charles River Laboratories Intl. Inc (CRL) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs KKR & Co Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.45 (market cap $11.14B), while KKR & Co Inc trades at $101 (market cap $87.28B). The key difference: KKR & Co Inc is far larger — about 7.8× Charles River Laboratories Intl. Inc's market cap, and KKR & Co Inc pays a 0.77% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | KKR | |
|---|---|---|
Market Cap | $11.14B | $87.28B |
Sector | Health | Financials |
52-Week High | $233.60 | $152.16 |
52-Week Low | $145.57 | $83.88 |
Enterprise Value | $14.00B | $12.80B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
KKR trades at $96.91, showing minimal daily movement (-0.03%). The stock maintains a bullish technical outlook with strong analyst support (89% buy ratings) and a consensus price target of $122.71, representing 27% upside potential. Recent developments include multiple strategic investments, including a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, signaling aggressive expansion.
KKR demonstrates solid fundamentals with $19.2B revenue and $2.37B net income for 2025. The company shows consistent earnings beats and strong cash flow generation. Key risks include volatile cash flow patterns and high leverage. With robust institutional backing and strategic growth initiatives, KKR appears well-positioned for continued expansion in alternative asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
